212 related articles for article (PubMed ID: 27246779)
1. Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Zheng X; Zheng R; Hu Y; Werngren J; Forsman LD; Mansjö M; Xu B; Hoffner S
Antimicrob Agents Chemother; 2016 Aug; 60(8):4786-92. PubMed ID: 27246779
[TBL] [Abstract][Full Text] [Related]
2. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Li D; Hu Y; Werngren J; Mansjö M; Zheng X; Drobniewski F; Hoffner S; Xu B
Antimicrob Agents Chemother; 2016 Sep; 60(9):5159-66. PubMed ID: 27297481
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
[TBL] [Abstract][Full Text] [Related]
7. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
8. The pyrazinamide susceptibility breakpoint above which combination therapy fails.
Gumbo T; Chigutsa E; Pasipanodya J; Visser M; van Helden PD; Sirgel FA; McIlleron H
J Antimicrob Chemother; 2014 Sep; 69(9):2420-5. PubMed ID: 24821594
[TBL] [Abstract][Full Text] [Related]
9. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
10. [A survey on resistance to second-line drugs in patients with pulmonary tuberculosis in Shanghai, China].
Shen X; Li J; Gao Q; Xu B; Mei J
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun; 34(6):451-3. PubMed ID: 21781519
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
[TBL] [Abstract][Full Text] [Related]
12. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Forsman LD; Jonsson J; Wagrell C; Werngren J; Mansjö M; Wijkander M; Groenheit R; Hammar U; Giske CG; Schön T; Bruchfeld J
Clin Infect Dis; 2019 Sep; 69(8):1394-1402. PubMed ID: 30561569
[TBL] [Abstract][Full Text] [Related]
13. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
Sun F; Li Y; Chen Y; Guan W; Jiang X; Wang X; Ren P; Li J; Shi J; He G; Wu M; Tang P; Wang F; Sheng Y; Huang F; Zhou Z; Huang H; Hong L; Liu Q; Zhang Y; Zhang W
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578402
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.
Xia Q; Zhao LL; Li F; Fan YM; Chen YY; Wu BB; Liu ZW; Pan AZ; Zhu M
Antimicrob Agents Chemother; 2015 Mar; 59(3):1690-5. PubMed ID: 25583712
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
[TBL] [Abstract][Full Text] [Related]
16. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis.
Zheng X; Ning Z; Drobniewski F; Yang J; Li Q; Zhang Z; Hu Y
Int J Antimicrob Agents; 2017 Feb; 49(2):183-188. PubMed ID: 28012685
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of multidrug-resistant tuberculosis in Switzerland.
Helbling P; Altpeter E; Egger JM; Zellweger JP
Swiss Med Wkly; 2014; 144():w14053. PubMed ID: 25474040
[TBL] [Abstract][Full Text] [Related]
18. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.
Tessema B; Beer J; Emmrich F; Sack U; Rodloff AC
Int J Tuberc Lung Dis; 2012 Jun; 16(6):805-11. PubMed ID: 22390880
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
